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The World Health Organization recommends direct observation of treatment (DOT) to
support patients with tuberculosis (TB) and to ensure treatment completion. As per
national programme guidelines in India, a DOT provider can be anyone who is acceptable
and accessible to the patient and accountable to the health system, except a family mem-
ber. This poses challenges among children with TB who may be more comfortable receiv-
ing medicines from their parents or family members than from unfamiliar DOT providers.
We conducted a non-inferiority trial to assess the effect of family DOT on treatment suc-
cess rates among children with newly diagnosed TB registered for treatment during June–
September 2012.
Methods
We randomly assigned all districts (n = 30) in Gujarat to the intervention (n = 15) or usual-
practice group (n = 15). Adult family members in the intervention districts were given the
choice to become their child’s DOT provider. DOT was provided by a non-family member in
the usual-practice districts. Using routinely collected clinic-based TB treatment cards, we
compared treatment success rates (cured and treatment completed) between the two
groups and the non-inferiority limit was kept at 5%.
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Results
Of 624 children with newly diagnosed TB, 359 (58%) were from intervention districts and
265 (42%) were from usual-practice districts. The two groups were similar with respect to
baseline characteristics including age, sex, type of TB, and initial body weight. The treat-
ment success rates were 344 (95.8%) and 247 (93.2%) (p = 0.11) among the intervention
and usual-practice groups respectively.
Conclusion
DOT provided by a family member is not inferior to DOT provided by a non-family member
among new TB cases in children and can attain international targets for treatment success.
Trial Registration
Clinical Trials Registry–India, National Institute of Medical Statistics (Indian Council of Medi-
cal Research) CTRI/2015/09/006229
Introduction
Directly observed treatment (DOT) is a supportive mechanism where a provider directly
observes a patient consuming their medication to ensure treatment adherence and is a core
component of the strategy recommended by the World Health Organization (WHO) to treat
tuberculosis (TB). A classic study from Chennai, India showed that supervised domiciliary care
was as effective as hospital-based care in achieving treatment success. Given the resource con-
straints and costs of hospitalizing TB patients and patient-inconvenience associated with pro-
longed hospitalization, supervised, ambulatory care (also referred to has DOT) became the
standard of care [1, 2]. Researchers conducted randomized trials during the late 1950s and
demonstrated similar patient outcomes for sanatoria-based and domiciliary based treatment,
thus paving the way for domiciliary treatment and DOT [2, 3]. Although widely accepted,
DOT has been the subject of much debate [4–9]. Concerns revolve around cost effectiveness of
the intervention, patient convenience, patient privacy, and the effect on treatment outcomes
[10–13]. Numerous studies have found no difference in treatment outcomes achieved under
self-administered treatment versus DOT [8, 14]. However, the validity of these studies has
been debated [15, 16,17,18]. DOT provision for children with TB has been a challenge and
deserving of additional research in the area of treatment delivery [13, 19,20,21].
As per Revised National TB Control Programme (RNTCP) guidelines in India, a DOT pro-
vider can be any person who is acceptable and accessible to the patient and accountable to the
health system, except a family member [22]. This poses challenges for treating children, who
may be more comfortable receiving medicines from their parents or family members than
from unfamiliar DOT providers. Additionally, DOT requires healthcare resources and can be
burdensome in terms of time and cost to the patient or their caretaker when attending for
direct observation [7]. To the best of our knowledge, there are no studies in India that com-
pared the treatment outcomes of children with TB based on the type of DOT provider. We
conducted a non-inferiority, cluster-randomized trial in Gujarat, India, to determine if TB
treatment success rates among children newly diagnosed with TB are non-inferior among
those that received RNTCP-recommended DOT and those who received observed treatment
from a family member.
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Methods
Setting
Gujarat is a state in western India with a population of 60.4 million [23]. TB control services in
Gujarat state have been provided by the RNTCP since 2004 and follows the WHO-recom-
mended DOTS strategy. Currently, there are 40,897 DOT centres across 30 districts in the
state. As per the RNTCP performance reports, from 2005–2011, the proportion of new paediat-
ric cases ranged from 5 to 7% among all registered cases. In 2011, 53,110 new TB cases were
registered under RNTCP; 3,219 were among children, of which, 94% were treated successfully
(cured or treatment completed) [23].
The RNTCP provides a patient wise box for each diagnosed case which contains packets of
loose drugs. The intensive phase consists of Isoniazid, Rifampicin, Pyrazinamide and Etham-
butol to be given under direct observation thrice a week on alternate days for 2 months (24
doses). The continuation phase consists of 4 months (18 weeks; 54 doses) of Isoniazid and
Rifampicin given thrice a week on alternate days, with the first dose of every weekly blister
being directly observed. The box remains with the DOT provider.
Since, the numbers of tablets are too many to consume, whenever required, DOT providers
are advised to crush the tablets, mix them with water, and then give to the child. It is the
responsibility of the DOT provider to supervise the process of drug consumption by the child.
If a child vomits within half an hour following observation, fresh dosages for all the drugs vom-
ited should be provided by the caregiver.
Study Design
We conducted a cluster randomized trial among children aged<15 years with newly diagnosed
TB and registered for treatment under the RNTCP in Gujarat. All 30 districts in Gujarat were
randomly assigned to the intervention group (n = 15) or the usual-practice group (n = 15).
Eight of the 30 districts have medical colleges where approximately 60% of all childhood TB
cases are diagnosed [23]. As the majority of the diagnosis of paediatric TB occurs at medical
colleges, districts were randomly selected keeping equitable distribution of districts with medi-
cal colleges among the intervention and usual-practice districts. Hence, districts were first
stratified based on the presence of medical colleges into two separate sets: one with a medical
college and the other districts without a medical college. In both sets, the districts were alpha-
betically arranged and given a serial number (i.e. the first set of districts were numbered serially
from 1 to 8 and in the other set numbered serially from 1 to 22). The first 4 random numbers
in the first group and first 11 random numbers in the second group were allocated to interven-
tion districts by study investigators.
Study Population and Study Period
We calculated the sample size on the basis of the null hypothesis that treatment success rates
would be similar among the intervention and usual-practice groups. Based on routinely col-
lected program data, the TB treatment success rate was assumed to be 95% in the usual-practice
arm (as well as in intervention group) and the non-inferiority limit was kept at 5% [23]. Using
a sample size calculator for non-inferiority trials, with 80% power and 95% confidence, a sam-
ple size of 472 was needed [24, 25]. This was inflated by an assumed design effect of 1.2 to
achieve a final sample size of 566. To achieve this sample size, we enrolled all children with
newly diagnosed TB registered for treatment in Gujarat from June to September of 2012. We
used standard diagnostic tools and case definitions provided in RNTCP guidelines [22]. Chil-
dren who required hospitalization were excluded from the study.
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Study Procedures
In the intervention districts, study staff visited all children newly diagnosed with TB and their
family members and offered the option of choosing family DOT. Family DOT was a strategy in
which anti-TB medications (all the doses in intensive and continuation phase) were adminis-
tered at home under the supervision of an adult household member. The adult family member
was father or mother in majority of cases, but included grandparents, siblings or other relatives/
guardians in rare instances. The children were enrolled after written informed consent was
obtained from an adult caretaker. There were no specific criteria related to education or occupa-
tion of the family member to qualify as DOT provider. If adult caretaker or child did not want
to have a family member provide DOT or there is no adult caretaker in the home, then they
were considered ineligible for the intervention. In such cases an alternative mechanism (i.e., gov-
ernment or community DOT provider) was assigned to the child. Similar to training provided
for community DOT providers (non-governmental DOT providers) the eligible family member
who wished to become the DOT provider was given onsite training (at home) by government
supervisory staff. The training focused on the DOTS strategy, the treatment process and its
duration, the role of DOT supervisors in ensuring TB treatment completion, and side effects of
anti-TB medications. The training also included component on how to manage episodes of
vomiting immediate after drug consumption. In the usual-practice districts, consent was unnec-
essary as no alteration was made to existing treatment guidelines. The patient intake was started
on 1st June 2012 and last patient enrolled on 30th September 2012. The Public Health System
was responsible for supervising and ensuring DOT for all TB patients included in the study. The
entire patient wise treatment box was provided to family member similar to a practice followed
for community DOT provider. As per RNTCP guidelines, when a patient was provided treat-
ment by a community DOT provider (non-governmental staff), there would be two treatment
cards for each patient: the original treatment card with the community DOT provider and a
duplicate treatment card at the health centre which was updated fortnightly by the government
supervisory staff. The same system was adopted for family DOT in the intervention districts and
the government-health staff updated TB treatment information. All participants were later vis-
ited by either a medical officer or a treatment supervisor assigned to their respective area. This
step was taken to verify whether each child was receiving family DOT or non-family DOT
according to study operating procedures. Treatment monitoring was done by following up of
the children as per RNTCP guidelines (clinical/bacteriological assessment at the end of 2
months, and at the end of treatment) [22]. During the review at 2 months, a non-satisfactory
response was determined by poor adherence to treatment, weight loss and worsening of symp-
toms. The intensive phase of treatment was extended for a month if clinical or bacteriological
non-response was noted. The final treatment outcome was declared after clinical and/or bacteri-
ological examination by the concerned medical officer of the area under whom the patient has
been registered. Final treatment outcomes were defined according to RNTCP guidelines [22]
The last Patient follow-up ended on 12th May 2013. Before implementation, we conducted one-
day training camps to familiarize RNTCP staff in all districts with the study protocol and proce-
dures RNTCP staff then enrolled participants and assigned them to the interventions.
Trial Registration
The authors confirm that all ongoing and related trials for this intervention are registered. Trial
registration number is CTRI/2015/09/006229 The Trial Registered Retrospectively. [URL http://
ctri.nic.in/Clinicaltrials/showallp.php?mid1=11438&EncHid=&userName=CTRI/2015/09/
006229] The major reason for not registering this study before enrolment of participants started
is that the authors believed that it is a community based trial and not a strict clinical RCT.
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Data Collection and Variables
We collected district-level health system and TB programme performance related characteris-
tics for both the intervention and usual-practice districts. These data were extracted from the
Gujarat State RNTCP programme performance reports [23]. Next, for all participants, we
reviewed standard TB treatment cards kept within the peripheral health centres and abstracted
information regarding TB treatment outcome, number of missed doses (as a measure of treat-
ment adherence), type of DOT provider, age, sex, initial body weight, initial sputum smear
microscopy result, site of TB disease and weight gain during treatment.
Data Analysis
All data were double-entered into a database created with EpiData (Version 3.1, EpiData Associa-
tion, Odense, Denmark). Discrepancies were corrected by going back to the source data. We per-
formed a cluster-adjusted (taking district as the primary sampling unit) analysis using STATA
(version 12.1, STATA Corp.). We compared patient-level baseline characteristics and treatment
success rates (along with 95% confidence intervals) between children with TB in the intervention
districts to those in the usual-practice districts using a chi-square test, Fischer’s exact test or clus-
ter-adjusted logistic regression as applicable. The level of significance was set at0.05. When com-
paring means, we used student’s t-test or its non-parametric alternative (WilcoxonMann
Whitney test) depending on whether the variable was normally distributed or not (as assessed by
Shapiro-Wilk test). The primary outcome was treatment success (cured and treatment completed).
In our analysis, we first compared the crude (unadjusted) treatment success rates of the two DOT
strategies. We then performed cluster-adjusted logistic regression and calculated adjusted treat-
ment success rates after adjusting for potential confounding effects of age, sex and type of TB, if
any. All analysis were adjusted for the clustering effect, taking district as primary sampling vari-
able. The difference in adjusted treatment success rates between the two groups along with 95%
confidence intervals around the difference was calculated. It was decided a priori that the new
intervention would be considered non-inferior if the lower limit of the confidence interval was
greater than -5%.We performed the analysis using two approaches, one intention-to-treat, and
another per-protocol. The primary analysis was by intention-to-treat approach as per initial ran-
domised allocation. The analysis was repeated (per-protocol analysis) after removal of participants
who were not receiving the treatment strategies according to the study protocol (i.e., those in the
usual-practice group who were receiving family DOT, and those in the intervention group receiv-
ing DOT by a non-family member). As a proxy indicator among children who successfully com-
pleted treatment, we compared treatment regularity (measured by number of missed doses) and
weight gain during treatment between children in the intervention and usual-practice groups.
Ethics Statement
Ethics approval was obtained from B J Medical College, Ahmedabad, Gujarat, and Ethics Advi-
sory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France,
for the use, reporting and publication of data. The children were enrolled after written
informed consent was obtained from an adult caretaker. In the usual-practice districts, consent
was unnecessary as no alteration was made to existing treatment guidelines. All data were safe-
guarded to protect patient confidentiality and no individual patient identifiers were retained.
Results
District-level health system, and TB programme related characteristics for the intervention and
usual-practice districts are shown in Table 1 [23]. The intervention and non-intervention
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districts were similar to each other on a host of health system related and TB performance indi-
cators including baseline treatment outcomes among paediatric TB patients. A total of 624
children with newly diagnosed TB were registered during the study period: 359 in the interven-
tion districts and 265 in the usual-practice districts under RNTCP. None of the children
required hospitalization; thus, all were included in the study. The CONSORT flow diagram on
enrolment, allocation, follow-up and analysis is shown in Fig 1.
Intention to Treat Analysis
Baseline characteristics among children newly diagnosed with TB in the intervention and
usual-practice groups were similar with respect to age, sex, pre-treatment sputum smear
results, type of TB, and pre-treatment body weight (Table 2). Thirty (4.8%) paediatric TB
patients were aged below 1 year and 190 (30%) were below 5 years. Treatment success rates
were 95.8% (95% CI: 94.1%–97.1%) and 93.2% (95% CI: 88.9%–95.9%) (p = 0.11) among the
intervention and usual-practice districts respectively. The respective adjusted treatment success
rates were 95.9% (95% CI: 94.7%–97.2%) and 92.9% (95% CI: 89.9%–96.0%). The difference in
treatment success rates between the two groups was 3.0% (95% CI: -0.7%–+6.7%). Since the
Table 1. Baseline characteristics of districts by intervention, year 2011 [23].






Population (n) 33,165,080 25,854,920
Health system infrastructure
TB Unita (n) 81 63
Peripheral Health Institutions (n) 1058 882
Designated Microscopic Centre (n) 440 308
Medical College (n) 8 6
Medical officer TB Unit 81 63
Senior Treatment Supervisor 81 63
TB program performance
Proportion of child TB cases of new cases 5.9% 5.2% <0.001
Proportion of smear-positive TB patients started on treatment
within seven days of diagnosis
92.4% 92.4% 0.94
Proportion of smear-positive TB patients registered within a
month of starting treatment
98.3% 97.5% 0.54
Treatment success rate of all new smear positive TB patients
(%)
87.5% 88.1% 0.68
Treatment outcomes of childrenb 2120 1099
Cured 333 (16%) 204 (18%) 0.37
Treatment completed 1664 (79%) 855 (78%)
Death 55 (3%) 26 (2%)
Failure 12 (1%) 4 (0.3%)
Defaulted 41 (2%) 15 (1%)
Transferred out 8 (0.3%) 4 (0.3%)
a Tuberculosis Units [TU] (geographical areas defined as sub-district level programme management units, each covering a population of 250000–500000
with TB diagnostic and treatment services being delivered through a network of primary, secondary and tertiary healthcare facilities)
b aged <15 years with newly diagnosed TB and registered for treatment under the RNTCP in Gujarat. Fischer’s exact test was used since several cells
had expected value less than 5.
doi:10.1371/journal.pone.0148488.t001
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lower limit of the 95% confidence interval (-0.7%) is greater than -5% (the non-inferiority
limit), the new intervention was concluded to be non-inferior to the existing intervention. The
actual design effect for the key outcome variable was found to be 1.02 (less than the assumed
1.2 in sample size calculations).
Fig 1. Flow diagram of study cohort of children with newly diagnosed TB registered in Gujarat State, India during June-September 2012.
doi:10.1371/journal.pone.0148488.g001
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The difference between treatment outcomes disaggregated by the type of TB is shown in
Table 3. It may be noted that the intervention was either non-inferior or superior to the usual-
practice group across the types of TB patients. Out of the total 101 new smear positive cases
(58 in intervention group and 43 among non-intervention group) 85 had converted to smear
negative at the end of two months (50 (86.2%) and 35 (81.4%) in the two groups respectively)
with 4 (6.9%) and 3 (7%) non-converters respectively (p = 0.23). At the end of treatment, 47
(81.0%) in the intervention group and 35 (81.4%) in the non-intervention group were bacterio-
logically cured (p = 0.22). Although default was a rare event (n = 14), when compared to treat-
ment success, risk of default was higher in the usual-practice districts as compared to
intervention districts (p = 0.03).
Per Protocol Analysis
Of 359 children in the intervention districts, 12 did not receive family DOT. Five of these chil-
dren did not have an eligible family member who could deliver DOT, and parents of the remain-
ing seven children were unable to record the treatment intake accurately or were anxious about
managing the side effects of anti-TB drugs and preferred a DOT provider allocated by the gov-
ernment health system. A Government DOT provider assumed DOT responsibilities in these
Table 2. Comparison of baseline characteristics among children with newly diagnosed TB, by treatment strategy, registered in Gujarat State,
India, June-September 2012.





Number % Number %
Total 359 100 265 100
Sex
Male 163 45.4 135 50.9 0.17
Female 196 54.6 130 49.1
Age in yearsa
0 to 1 year 20 5.6 10 3.8 0.57
2 to 5 years 90 25.3 70 26.4
6 to10 years 124 34.8 85 32.1
11 to 14 years 122 34.3 100 37.7
Disease Classification
New smear positive pulmonary TB 58 16.2 43 16.2 0.14
New smear negative pulmonary TB 28 7.8 34 12.8
New extrapulmonary TB 196 54.6 143 54.0
New Otherb 77 21.4 45 17.0
Initial Weight (in Kg)c
Median (IQR) 17 (11) 17 (13) 0.54
Kg = Kilogram, TB = Tuberculosis, DOT = Directly Observed Treatment, SD = Standard Deviation, Treatment success = Cured or treatment Completed.
Note: Chi-square test was used for assessing difference between the proportions.
a Age was not recorded for 3 patients.
b A patient who does not fit into the any of the types mentioned above (smear positive, smear negative, extra pulmonary), where bacteriological evidence
could not be demonstrated but decision to treat was taken on clinical grounds would continue to be recorded and reported as “OTHERS”.
c Initial weight was not recorded for 1 person; Wilcoxon Mann Whitney test (a non-parametric test) was used for assessing statistical significance since the
variable was not normally distributed.
doi:10.1371/journal.pone.0148488.t002
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cases. Therefore, a total of 347 children received family DOT, an acceptance rate of 97%. Of the
347 who received family-DOT, 189 received DOT from their father, 118 from their mother, 7
from grandparents, 14 from siblings, and 19 from others. Contrary to guidelines, eight (3%) of
265 children were receiving DOT by a family member in the usual-practice districts. Among the
remaining patients, 103 received DOT from a government health care worker, 151 from com-
munity DOT providers, and 3 did not have the type of DOT provider recorded.
Table 3. Comparison of treatment outcomes among children with newly diagnosed TB, stratified by disease classification and treatment strategy,
registered in Gujarat State, India, June-September 2012.





Number % Number %
All TB patients 359 100 265 100
Cured 47 13.1 35 13.2 0.17
Treatment completed 297 82.7 212 80.0
Death 5 1.4 6 2.3
Default 4 1.1 10 3.8
Transfer Out 3 0.8 2 0.8
Failure 3 0.8 0 0.0
New smear-positive PTB 58 100 43 100
Cured 47 81.0 35 81.4 0.22
Treatment completed 2 3.4 4 9.3
Death 3 5.2 3 7.0
Default 3 5.2 0 0.0
Transfer Out 0 0.0 1 2.3
Failure 3 5.2 0 0.0
New smear-negative PTB 28 100 34 100
Treatment completed 28 100.0 33 97.1 1.0
Death 0 0.0 1 2.9
Default 0 0.0 0 0.0
Transfer Out 0 0.0 0 0.0
Failure 0 0.0 0 0.0
New others a 77 100 45 100
Treatment completed 76 98.7 42 93.3 0.05
Death 1 1.3 0 0.0
Default 0 0.0 3 6.7
Transfer Out 0 0.0 0 0.0
Failure 0 0.0 0 0.0
New extra-pulmonary TB 196 100 143 100
Treatment completed 191 97.5 133 93.0 0.02
Death 1 0.5 2 1.4
Default 1 0.5 7 4.9
Transfer Out 3 1.5 1 0.7
Failure 0 0.0 0 0.0
a A patient who does not fit into the any of the types mentioned above (smear positive, smear negative, extra pulmonary), where bacteriological evidence
could not be demonstrated but decision to treat was taken on clinical grounds would continue to be recorded and reported as “OTHERS”.
Note: Fischer’s exact test was used for assessing difference between the proportions as the expected cell values is many of the cells were less than 5.
doi:10.1371/journal.pone.0148488.t003
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The analysis was repeated after excluding the 20 children who were not receiving treatment
according to the initial study allocation (per protocol analysis). The adjusted treatment success
rates among the intervention group (n = 347) and usual-practice group (n = 257) were 95.8%
(95% CI: 94.6%-97.0%) and 92.7% (95% CI: 89.6%-95.8%) (p = 0.10), respectively, with a dif-
ference between the two groups of 3.1% (95% CI: -0.6%-6.9%).
Our comparison of treatment regularity and weight gain during treatment, by treatment
strategy are presented in Table 4. There were no statistically significant differences in these
characteristics between the two groups.
Since the treatment success rates were high across subgroups of exposure variables (like sex,
type of TB, age groups) with little differences from a clinical or programmatic perspective and
unavailability of sufficient numbers across the sub-groups, we refrained from exploring effect
modification or interaction.
Discussion
We observed a high acceptance rate (97%) for family DOT. Family DOT achieved similar treat-
ment success rates to that of non-family member DOT among children with TB in Gujarat.
The intervention and the usual-practice groups were similar to each other by age, sex, type of
TB and baseline weight. This indicates the success of randomization and that the groups were
comparable to each other with the difference, or lack of, in outcomes being more likely to be
attributable to the intervention. Both strategies achieved the desired WHO target for treatment
success under programmatic conditions [26]. These results support those obtained in earlier
studies among patients of all age groups which showed that family-member and community
DOTS strategies can achieve desired success rates [27–29]. Since the study was conducted
under routine programme conditions, these results may be generalizable to other similar
settings.
The high level of treatment adherence recorded in the intervention group indicates good
uptake of the intervention among family members. Satisfactory weight gain was observed dur-
ing treatment in both groups, which is an indirect indicator for response to anti-TB treatment
[30]. Although family DOT was widely accepted, there were situations in which there was no
Table 4. Comparison of individual level factors among children successfully treated for TB, by treatment strategy, registered in Gujarat State,
India, June-September 2012.





Number % Number %
Total (treatment success) 344 100 247 100
Number of Missed doses during treatmenta
None 271 78.8 181 73.9 0.19
1–3 doses 47 13.7 35 14.3
4 doses 26 7.6 29 11.8
Weight gain during treatment (in Kg)
Mean (SD)b 2.86 (2.30) 2.67 (1.69) 0.88
a Treatment card was missing information on dosage information for 2 children. Chi-square test was used for assessing difference between the
proportions.
b Weight gain could not be determined for 46 children whose end of treatment information weight was missing. We used Wilcoxon Mann Whitney test (a
non-parametric test) for assessing statistical significance since the variable was not normally distributed.
doi:10.1371/journal.pone.0148488.t004
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adult family member available or qualified to provide DOT, and situations when parents pre-
ferred a health system allocated DOT provider. Therefore, it is important for TB programmes
to maintain capacity to provide DOT providers while allowing families the option to provide
DOT for their children. Although we found no statistical difference in treatment outcomes
according to treatment strategy, a total of 11 deaths (5 from the family-DOT group and 6 from
the usual practice group) were observed among this cohort of paediatric patients. This is con-
cerning and worth noting. Unfortunately, we are unable to comment on the exact causes of
death, or to assess potential causes of death with data collected for this study.
One argument against the inclusion of a family member as a DOT provider is that “cultures
with strong matriarchal or patriarchal structures, it is not realistic to believe that any member of
the family can insist on any behaviour by the dominant family head” [15]. While this may not
be true even in adults with TB, the same certainly not apply to children who, given the cultural
context in India, are likely to follow instructions and encouragement by their parents or guard-
ians. A Cochrane review suggested that DOT “is expensive to implement, and there appears to
be no sound reason to advocate its routine use until we better understand the situations in which
it may be beneficial” [9]. The family-member DOT strategy has the advantage over standard
DOT in that it does not involve community volunteers such as ASHA (Accredited Social
Health Activist) or Anganawadi workers, who are becoming increasingly overloaded because
of the many different health programmes requesting their help.
Study Strengths
This study was the first to assess the effectiveness of family-based DOT conducted in children
in India. It was performed in routine program settings and hence provides evidence for wider
scale-up. Randomization was successful and resulted in two comparable groups enabling a
clean assessment of the effect of the intervention. The study was conducted across the entire
state of Gujarat ensuring a large representative sample. There were very few children who did
not adhere to the assigned treatment method outlined in the protocol (e.g., family-based vs.
non-family-based DOT), and even after the removal of these children there was no difference
in the findings. Finally, this study demonstrated that family members can be easily trained to
provide DOT for children which can potentially lead to a more affordable strategy allowing for
shifting of resources to accelerate other TB program activities.
Limitations of the Study
There were some limitations. First, the study was performed in a programmatic setting and
used programmatic definitions for treatment outcomes, in which, the majority of paediatric TB
patient’s outcome was not verified microbiologically. This is an acknowledged, general chal-
lenge in children with TB given the difficulties in collecting good quality sputum specimen for
microbiologic examination. This is even more challenging at the end of the treatment when
most patients are symptom-free and cannot produce sputum. Second, the study does not have
data on long term follow-up, such as relapse rates for study participants, which should be a
topic for future research. We intend to follow-up this cohort for a period of one year to assess
the relapse rates and report on this separately. Because of the study design, no blinding could
be performed. Third, while the two groups were similar with reference to age and baseline
weight, we did not have any information with respect to height. Hence, we will not be able pro-
vide information on the proportion of failure to thrive or any other measure of malnutrition at
baseline. Given the potential of this variable to act as a possible confounder, we acknowledge
this missing information a limitation. The same limitation is applied for other comorbid situa-
tions such as diabetes and HIV. Fourth, presence of other TB patients in the household and
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whether they functioned as treatment observers for the study group was not systematically cap-
tured. Hence we are not able to comment if the two groups were different with respect to this
variable and adjust for the same in analysis. Fifth, we could not perform a drug susceptibility
test among children who failed treatment and hence do not have any information on acquired
drug resistance. Finally, side effects from anti-TB medications were not documented
completely and hence we cannot assess if differential rates of such side effects occurred among
the two groups.
Implications and Recommendations
Given the resource limitations in India, a shift toward family-based DOT for children with TB
could decrease the work load of an overburdened health system and reduce the cost of treat-
ment of childhood TB. Based on results of this study, India has revised national guidelines to
allow the option of having a family member provide DOT for children with TB [31, 32].
Conclusion
DOT by a family member is not inferior to that provided by a non-family member among new
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